Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polypharmacy and Crohn's disease.

R K Cross1, K T Wilson, D G Binion

  • 1Division of Gastroenterology and Hepatology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. rcross@medicine.umaryland.edu

Alimentary Pharmacology & Therapeutics
|May 11, 2005
PubMed
Summary

Polypharmacy is common in Crohn's disease, affecting 50% of patients. It is linked to worse disease activity and lower quality of life, necessitating better treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Opioid Analgesics Do Not Improve Abdominal Pain or Quality of Life in Crohn's Disease.

Digestive diseases and sciences·2019
Same author

EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis.

Oncogene·2017
Same author

TRPM2 ion channels regulate macrophage polarization and gastric inflammation during Helicobacter pylori infection.

Mucosal immunology·2016
Same author

Myeloid translocation genes differentially regulate colorectal cancer programs.

Oncogene·2016
Same author

Pathogenic Helicobacter pylori strains translocate DNA and activate TLR9 via the cancer-associated cag type IV secretion system.

Oncogene·2016
Same author

Epigenetic silencing of miR-124 prevents spermine oxidase regulation: implications for Helicobacter pylori-induced gastric cancer.

Oncogene·2016

Area of Science:

  • Gastroenterology
  • Clinical Pharmacy
  • Inflammatory Bowel Disease Research

Background:

  • Polypharmacy lacks a clear definition in Crohn's disease management.
  • Understanding polypharmacy prevalence is crucial for patient care.

Purpose of the Study:

  • To define and determine the prevalence of polypharmacy in Crohn's disease patients.
  • To identify factors associated with polypharmacy.
  • To assess the consequences of polypharmacy on disease activity and quality of life.

Main Methods:

  • A retrospective review of 291 Crohn's disease patients was conducted.
  • Polypharmacy was defined as minor (2-4 medications) or major (≥5 medications).
  • Disease activity was assessed using the Harvey-Bradshaw Index (HBI) and quality of life via the Short Inflammatory Bowel Disease Questionnaire (SIBDQ).

Related Experiment Videos

Main Results:

  • Major polypharmacy was observed in 50% of patients.
  • Higher HBI scores and lower SIBDQ scores were associated with minor and major polypharmacy compared to <2 medications.
  • Predictors of major polypharmacy included age >40, disease duration >10 years, and female sex.

Conclusions:

  • Polypharmacy is prevalent in Crohn's disease and associated with increased disease activity and reduced quality of life.
  • Age, disease duration, and female sex are significant predictors of polypharmacy.
  • Optimized treatment algorithms are needed to manage polypharmacy in Crohn's disease.